Journal profile · PHARMACOLOGY & PHARMACY
Drug Discoveries and Therapeutics
ISSN 1881-7831 · eISSN 1881-784X · International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.)
Drug Discoveries and Therapeutics: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.3 (journal website); fully open access; APC about USD 140; 59 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Drug Discoveries and Therapeutics is published by International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.) and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research and Invertebrate Immune Response Mechanisms, together about 21.6% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Drug Discoveries & Therapeutics publishes contributions in all fields of pharmaceutical and therapeutic research such as medicinal chemistry, pharmacology, pharmaceutical analysis, pharmaceutics, pharmaceutical administration, and experimental and clinical studies of effects, mechanisms, or uses of various treatments. Studies in drug-related fields such as biology, biochemistry, physiology, microbiology, and immunology are also within the scope of this journal.
From the journal's Aims & Scope
Research area (LetPub): PHARMACOLOGY & PHARMACY
Editor-in-chief Nobuyoshi AKIMITSUPublisher website
Editorial board by country: 7 in mainland China (about 26%); most named Japan 11, Mainland China 7, United States 5, Hong Kong, China 2, Germany 1 (27 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- COVID-19 Clinical Research StudiesMedicine7.4%
- SARS-CoV-2 and COVID-19 ResearchMedicine7.1%
- Invertebrate Immune Response MechanismsImmunology and Microbiology7.1%
- Hepatocellular Carcinoma Treatment and PrognosisMedicine5.7%
- Insect Utilization and EffectsAgricultural and Biological Sciences5.2%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics4.5%
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics4.5%
- Pharmacological Effects of Natural CompoundsPharmacology, Toxicology and Pharmaceutics4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePubMedCASDOAJPublisher website
Other: EBSCO, Journal Citation Reports | Clarivate Analytics, EBSCO Information Services, National Diet Library, Japan, Japan Medical Abstracts Society, JDream III, J-GLOBAL
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 1.3Publisher website ·
- CiteScore 2026-06
- 3.2LetPub ·
- SJR 2026-06
- 0.26LetPub ·
- SNIP 2026-06
- 0LetPub ·
- h-index
- 43OpenAlex ·
- i10-index
- 346OpenAlex ·
- 2-year mean citedness
- 2.01OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 99.38%LetPub ·
Volume
- Articles per year
- 50LetPub ·
Articles by year OpenAlex count · 878 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 43 | 43 | 4 |
| 2025 | 59 | 59 | 175 |
| 2024 | 58 | 58 | 143 |
| 2023 | 59 | 59 | 284 |
| 2022 | 60 | 60 | 396 |
| 2021 | 58 | 58 | 594 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | USD 140 / USD 340 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Manuscript length
- ≤ 5,000 words
- Cover letter
- Required
Article types accepted18, with length limits
- brief reportof incomplete or preliminary findings. Brief Reports should not exceed 3,000 words in length (excluding references) and should be limited to amain text ≤ 3,000 words
- brief reportsDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …Length not stated
- case reportng medications will also be considered. Case Reports should not exceed 3,000 words in length (excluding references). Communications are short,main text ≤ 3,000 words
- case reportsDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …Length not stated
- communicationCommunications are short, timely pieces that spotlight new research findings or policy issues of interest to the field of global health and medical practice tha…Length not stated
- communicationsDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …Length not stated
- editorialence oriented for clinical application. Editorials should not exceed 1,000 words in length (excluding references) and should be limited to amain text ≤ 1,000 words
- editorialsDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …Length not stated
- letterLetters should present considered opinions in response to articles published in Drug Discoveries & Therapeutics in the last 6 months or issues of general intere…Length not stated
- lettersDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …Length not stated
- mini reviewgures and/or tables and 100 references. Mini reviews are also accepted, which should not exceed 4,000 words in length (excluding references) and should be limit…main text ≤ 4,000 words
- newsNews articles should report the latest events in health sciences and medical research from around the world.Length not stated
- original articlession, Acknowledgments, and References. Original articles should not exceed 5,000 words in length (excluding references) and should be limited to amain text ≤ 5,000 words
- original articlesDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …Length not stated
- policy forumPolicy Forum articles discuss research and policy issues in areas related to life science such as public health, the medical care system, and social science and…Length not stated
- policy forum articlesDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …Length not stated
- reviews within an area of research. Normally, reviews should not exceed 8,000 words in length (excluding references) and should be limited to amain text ≤ 8,000 words
- reviewsDrug Discoveries & Therapeutics publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, Communications, Editorials, News, and …Length not stated
Policy excerpts from the journal's websitePublication ethics, Peer review, Trial registration / reporting guidelines
- Publication ethics
Formal review and approval (or waiver) by an appropriate institutional review board or ethics committee is required for studies involving human participants or animals. Model summary
For all manuscripts reporting data from studies involving human participants or animals, formal review and approval, or formal review and waiver, by an appropriate institutional review board or ethics committee is required and should be described in the Methods section.
Source ↗Publisher website ·- Peer review
Peer review is performed; the journal states it will perform an especially prompt review. Model summary
Drug Discoveries & Therapeutics will perform an especially prompt review to encourage innovative work. All original research will be subjected to a rigorous standard of peer review and will be edited by experienced copy editors to the highest standards.
Source ↗Publisher website ·- Trial registration / reporting guidelines
Clinical trial registration in a public trial registry at or before first patient enrollment is a condition of consideration for publication; the trial registration number will be published at the end of the Abstract. Model summary
Registration of clinical trials in a public trial registry at or before the time of first patient enrollment is a condition of consideration for publication in Drug Discoveries & Therapeutics, and the trial registration number will be published at the end of the Abstract.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.)
- ISSN
- 1881-7831
- Electronic ISSN
- 1881-784X
- Official links
- Journal homepage ↗OpenAlex
FAQ
Frequently asked questions about Drug Discoveries and Therapeutics
What CAS zone is Drug Discoveries and Therapeutics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Drug Discoveries and Therapeutics is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Drug Discoveries and Therapeutics?
The journal's website gives an impact factor of 1.3; this is the journal's own figure, as LetPub lists none for it; CiteScore 3.2, h-index 43.
What are the manuscript requirements of Drug Discoveries and Therapeutics?
According to the journal's author guidelines: Manuscript length: ≤ 5,000 words; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Drug Discoveries and Therapeutics based?
Of the 27 board members whose country the journal's board page names, 7 (about 26%) are in mainland China; the countries named most often are Japan (11), Mainland China (7) and United States (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Drug Discoveries and Therapeutics?
According to LetPub and DOAJ records, Drug Discoveries and Therapeutics is indexed in ESCI and Scopus. The journal's website also lists Web of Science, PubMed, CAS and DOAJ; that list has not been checked against each database.
Is Drug Discoveries and Therapeutics open access, and what is the APC?
Drug Discoveries and Therapeutics is a fully open-access journal. APC about USD 140.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .